Literature DB >> 19534712

Oral vaccine delivery--new strategies and technologies.

Pavla Simerska1, Peter M Moyle, Colleen Olive, Istvan Toth.   

Abstract

Although most commercial vaccines are delivered by injection, there is an increasing interest in needle-free vaccine delivery for reasons including the ability to elicit immune responses at mucosal surfaces, ease of administration, and the ability to administer vaccines without the need for trained medical professionals. This review summarizes strategies and technologies that are being used to improve oral vaccine absorption. Peptides and proteins, which comprise important vaccine components, exhibit unfavorable physicochemical properties including degradation in the gastrointestinal tract, and poor transport across the intestinal wall, which hinder oral vaccine development. Approaches to overcome these obstacles aim to provide new vaccines and delivery systems that are capable of eliciting protective immune responses, and are making an impact on current vaccine development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19534712     DOI: 10.2174/156720109789000537

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  10 in total

Review 1.  Recent advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents.

Authors:  Anumita Chaudhury; Surajit Das
Journal:  AAPS PharmSciTech       Date:  2010-12-11       Impact factor: 3.246

2.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

3.  Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array.

Authors:  Zhi Ding; Suzanne M Bal; Stefan Romeijn; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-03-17       Impact factor: 4.200

4.  Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

Authors:  Abby Jones; Catharine Bosio; Angela Duffy; Andrew Goodyear; Martin Schriefer; Steven Dow
Journal:  Vaccine       Date:  2010-06-19       Impact factor: 3.641

5.  Microneedle-based two-step transdermal delivery of Langerhans cell-targeting immunoliposomes induces a Th1-biased immune response.

Authors:  Yingjie Yu; Huan Wang; Beibei Guo; Bingkai Wang; Zhan Wan; Yunchang Zhang; Linhong Sun; Feng Yang
Journal:  Eur J Pharm Biopharm       Date:  2022-06-15       Impact factor: 5.589

6.  The hows and whys of constructing a native recombinant cholera vaccine.

Authors:  Mina Boustanshenas; Bita Bakhshi
Journal:  Bioengineered       Date:  2013-09-16       Impact factor: 3.269

7.  An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model.

Authors:  Marli S P Azevedo; Ana Maria Gonzalez; Lijuan Yuan; Kwang-Il Jeong; Cristiana Iosef; Trang Van Nguyen; Karin Lovgren-Bengtsson; Bror Morein; Linda J Saif
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

Review 8.  COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology.

Authors:  Hyun Jee Han; Chinekwu Nwagwu; Obumneme Anyim; Chinedu Ekweremadu; San Kim
Journal:  Int Immunopharmacol       Date:  2020-12-02       Impact factor: 4.932

Review 9.  Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit.

Authors:  Bharti Mangla; Shamama Javed; Muhammad H Sultan; Waquar Ahsan; Geeta Aggarwal; Kanchan Kohli
Journal:  Front Pharmacol       Date:  2022-01-11       Impact factor: 5.810

Review 10.  Vaccine and vaccination as a part of human life: In view of COVID-19.

Authors:  Megha K B; Seema A Nayar; Mohanan P V
Journal:  Biotechnol J       Date:  2021-11-21       Impact factor: 5.726

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.